342 related articles for article (PubMed ID: 25734218)
1. Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.
Bailey RA; Vijapurkar U; Meininger GE; Rupnow MF; Blonde L
Am J Manag Care; 2014 Dec; 20(13 Suppl):s296-305. PubMed ID: 25734218
[TBL] [Abstract][Full Text] [Related]
2. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Bailey RA; Damaraju CV; Martin SC; Meininger GE; Rupnow MF; Blonde L
Am J Manag Care; 2014 Jan; 20(1 Suppl):s16-24. PubMed ID: 24512193
[TBL] [Abstract][Full Text] [Related]
3. Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
Bailey RA; Vijapurkar U; Meininger G; Rupnow MF; Blonde L
Clin Ther; 2015 May; 37(5):1045-54. PubMed ID: 25795432
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Schernthaner G; Gross JL; Rosenstock J; Guarisco M; Fu M; Yee J; Kawaguchi M; Canovatchel W; Meininger G
Diabetes Care; 2013 Sep; 36(9):2508-15. PubMed ID: 23564919
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
[TBL] [Abstract][Full Text] [Related]
6. A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
Patel CA; Bailey RA; Vijapurkar U; Meininger G; Blonde L
BMC Health Serv Res; 2016 Aug; 16(a):356. PubMed ID: 27495291
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Forst T; Guthrie R; Goldenberg R; Yee J; Vijapurkar U; Meininger G; Stein P
Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
9. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
Schernthaner G; Lavalle-González FJ; Davidson JA; Jodon H; Vijapurkar U; Qiu R; Canovatchel W
Postgrad Med; 2016 Nov; 128(8):725-730. PubMed ID: 27391951
[TBL] [Abstract][Full Text] [Related]
10. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes.
Traina S; Guthrie R; Slee A
Postgrad Med; 2014 May; 126(3):7-15. PubMed ID: 24918788
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
Lavalle-González FJ; Eliaschewitz FG; Cerdas S; Chacon Mdel P; Tong C; Alba M
Curr Med Res Opin; 2016; 32(3):427-39. PubMed ID: 26579834
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
[TBL] [Abstract][Full Text] [Related]
14. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials.
Blonde L; Woo V; Mathieu C; Yee J; Vijapurkar U; Canovatchel W; Meininger G
Curr Med Res Opin; 2015 Nov; 31(11):1993-2000. PubMed ID: 26373629
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
[TBL] [Abstract][Full Text] [Related]
16. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Nicolle LE; Capuano G; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Nyirjesy P; Zhao Y; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
Scott R; Loeys T; Davies MJ; Engel SS;
Diabetes Obes Metab; 2008 Sep; 10(10):959-69. PubMed ID: 18201203
[TBL] [Abstract][Full Text] [Related]
19. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
Olansky L; Reasner C; Seck TL; Williams-Herman DE; Chen M; Terranella L; Mehta A; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2011 Sep; 13(9):841-9. PubMed ID: 21535346
[TBL] [Abstract][Full Text] [Related]
20. Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.
Lafeuille MH; Grittner AM; Gravel J; Bailey RA; Martin S; Garber L; Duh MS; Lefebvre P
J Med Econ; 2015 Feb; 18(2):113-25. PubMed ID: 25350645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]